Search

Your search keyword '"Degennaro, E."' showing total 3 results
Start Over Author "Degennaro, E."
3 results on '"Degennaro, E."'

2. Delphi consensus on the current clinical and therapeutic knowledge on Anderson-Fabry disease

Author

Concolino, D, Degennaro, E, Parini, R, Antuzzi, D, Bembi, B, Benso, A, Carraro, G, Chimenti, C, Colla, L, Cuonzo, M, Del Rosso, G, Diomedi, M, Feliciani, C, Feriozzi, S, Ficcadenti, A, Frustaci, A, Gnarra, M, Maccarone, M, Mancuso, M, Matucci, A, Mignani, R, Musumeci, B, Nencini, P, Piga, S, Pisani, A, Re, F, Salviati, A, Spada, M, Vultaggio, A, Zachara, Zedde, E, Zoli, P, Concolino, D., Degennaro, E., Parini, R., Antuzzi, D., Bembi, B., Benso, A., Carraro, G., Chimenti, C., Colla, L., Cuonzo, M. T., Del Rosso, G., Diomedi, M., Feliciani, C., Feriozzi, S., Ficcadenti, A., Frustaci, A., Gnarra, M., Maccarone, M., Mancuso, M., Matucci, A., Mignani, R., Musumeci, B., Nencini, P., Piga, S., Pisani, A., Re, F., Salviati, A., Spada, M., Vultaggio, A., Zachara, E., Zedde, M. L., and Zoli, P. G.

Subjects
Male, medicine.medical_specialty, Delphi Technique, Vital signs, Delphi method, Practice Patterns, Disease, Electrocardiography, Fabry disease, diagnosis, treatment, management, Diagnosis, Ambulatory, Biopsy, Internal Medicine, Medicine, Humans, Enzyme Replacement Therapy, Disease management (health), Practice Patterns, Physicians', Intensive care medicine, Adverse effect, Settore MED/14 - Nefrologia, Physicians', medicine.diagnostic_test, business.industry, Management, Treatment, Disease Management, Disease Progression, Electrocardiography, Ambulatory, Fabry Disease, Female, Genetic Diseases, X-Linked, Physician's Practice Patterns, Medicine (all), Enzyme replacement therapy, X-Linked, medicine.disease, Settore MED/03 - Genetica Medica, Genetic Diseases, Physical therapy, Settore MED/26 - Neurologia, business, Diagnosi, Human
Abstract

Background Management of Anderson–Fabry disease (AFD) is contentious, particularly regarding enzyme replacement therapy (ERT). We report results of a Delphi consensus panel on AFD management. Methods A survey to gauge consensus among AFD experts was distributed online and responses were analysed. Statements on: 1) diagnosis; 2) when starting ERT; 3) management of ERT infusion and adverse reactions; and 4) follow-up/monitoring response to therapy and progression of disease were included. Responses without consensus were discussed with an enlarged panel and modified to reach consensus. Results 15 experts responded to the survey. After plenary discussion among the enlarged panel, consensus was reached on most statements. Key points were the use of a target organ biopsy to show Gb3 deposits in symptomatic women with negative molecular analysis, the need for ERT in symptomatic women and in all patients with persistent signs and symptoms ± organ damage. It was agreed to assess vital signs before ERT administration and use a 0.2 μL filter on infusion to reduce the risk of adverse reactions, that serum should be drawn prior to the first infusion for anti-agalsidase antibody analysis to have a baseline value if a subsequent adverse reaction appears, and that pre-medication is required in those with prior infusion reactions. Holter ECG monitoring, cardiac and brain MRI, renal parameters, and abdominal ultrasound were considered important for the assessment of disease progression and response at ERT. Conclusions This consensus supplies guidance to healthcare providers on best practice in the management of patients with AFD and indicates a need for more guidance.

Published
2014

3. Delphi consensus on the current clinical and therapeutic knowledge on Anderson-Fabry disease.

Author

Concolino D, Degennaro E, and Parini R

Subjects
Disease Management, Disease Progression, Electrocardiography, Ambulatory, Fabry Disease diagnosis, Fabry Disease genetics, Female, Genetic Diseases, X-Linked therapy, Humans, Male, Practice Patterns, Physicians', Delphi Technique, Enzyme Replacement Therapy, Fabry Disease therapy
Abstract

Background: Management of Anderson-Fabry disease (AFD) is contentious, particularly regarding enzyme replacement therapy (ERT). We report results of a Delphi consensus panel on AFD management., Methods: A survey to gauge consensus among AFD experts was distributed online and responses were analysed. Statements on: 1) diagnosis; 2) when starting ERT; 3) management of ERT infusion and adverse reactions; and 4) follow-up/monitoring response to therapy and progression of disease were included. Responses without consensus were discussed with an enlarged panel and modified to reach consensus., Results: 15 experts responded to the survey. After plenary discussion among the enlarged panel, consensus was reached on most statements. Key points were the use of a target organ biopsy to show Gb3 deposits in symptomatic women with negative molecular analysis, the need for ERT in symptomatic women and in all patients with persistent signs and symptoms ± organ damage. It was agreed to assess vital signs before ERT administration and use a 0.2 μL filter on infusion to reduce the risk of adverse reactions, that serum should be drawn prior to the first infusion for anti-agalsidase antibody analysis to have a baseline value if a subsequent adverse reaction appears, and that pre-medication is required in those with prior infusion reactions. Holter ECG monitoring, cardiac and brain MRI, renal parameters, and abdominal ultrasound were considered important for the assessment of disease progression and response at ERT., Conclusions: This consensus supplies guidance to healthcare providers on best practice in the management of patients with AFD and indicates a need for more guidance., (Copyright © 2014 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.)

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results